| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
381,510,000 |
| Market
Cap: |
169.20(M) |
| Last
Volume: |
4,513,016 |
Avg
Vol: |
4,500,422 |
| 52
Week Range: |
$0.4435 - $2.04 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Agenus is a clinical-stage immuno-oncology (I-O) company engaged in the development of a pipeline of immune checkpoint antibodies, adoptive cell therapies and neoantigen cancer vaccines, to fight cancer and infections. Co.'s antibody candidates are balstilimab (an anti-PD-1 antibody) and zalifrelimab (an anti-CTLA-4 antibody), which are in Phase 2 trials as both a monotherapy (balstilimab) and combination therapy (balstilimab/zalifrelimab) for treatment of patients with second-line cervical cancer. Co. is also developing an anti-CTLA-4 antibody, botensilimab (also known as AGEN1181), which is designed to improve the magnitude of responses to first-generation anti-CTLA-4 molecules.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
500,000 |
525,000 |
525,000 |
525,000 |
| Total Buy Value |
$324,050 |
$343,050 |
$343,050 |
$343,050 |
| Total People Bought |
1 |
2 |
2 |
2 |
| Total Buy Transactions |
1 |
2 |
2 |
2 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Armen Garo H |
Chairman & CEO |
• – – |
2015-09-16 |
4 |
A |
$6.61 |
$553,237 |
D/D |
83,697 |
1,393,304 |
|
- |
|
| Malik Shahzad |
Director |
– • – |
2015-05-27 |
4 |
A |
$6.30 |
$10,000,003 |
I/I |
1,587,302 |
1,587,302 |
|
- |
|
| Malik Shahzad |
Director |
– • – |
2015-04-29 |
4 |
S |
$7.02 |
$2,858,809 |
I/I |
(407,377) |
0 |
|
- |
|
| Malik Shahzad |
Director |
– • – |
2015-04-28 |
4 |
S |
$7.16 |
$5,012,560 |
I/I |
(700,000) |
407,377 |
|
- |
|
| Incyte Corp |
10% Owner |
– – • |
2015-02-18 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
7,763,968 |
|
- |
|
| Qvt Fund V Lp |
10% Owner |
– – • |
2015-01-09 |
4 |
S |
$5.18 |
$12,451,322 |
I/I |
(2,343,630) |
6,915,630 |
|
- |
|
| Baysal Ozer |
CBO |
• – – |
2015-01-02 |
4 |
A |
$3.98 |
$24,875 |
D/D |
6,250 |
15,600 |
|
- |
|
| Armen Garo H |
Chairman & CEO |
• – – |
2014-06-27 |
4 |
D |
$3.44 |
$1,310,921 |
D/D |
(369,846) |
1,309,567 |
|
- |
|
| Armen Garo H |
Chairman & CEO |
• – – |
2014-06-02 |
4 |
A |
$2.70 |
$13,199 |
D/D |
4,886 |
1,679,413 |
|
- |
|
| Malik Shahzad |
Director |
– • – |
2014-05-08 |
4 |
A |
$3.00 |
$333,756 |
I/I |
111,289 |
1,107,377 |
|
- |
|
| Armen Garo H |
Chairman & CEO |
• – – |
2014-05-01 |
4 |
A |
$2.78 |
$13,198 |
D/D |
4,740 |
1,674,527 |
|
- |
|
186 Records found
|
|
Page 8 of 8 |
|
|
